SAS Output

20-AUG-2018 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP 1 Y 1 CVP + Inotuzumab dose level 1 38 5 0 0 0 0 0 06/13/2014 3 3
        2 CVP + Inotuzumab dose level 2   5 0 0 0 0 0      
        3 CVP + Inotuzumab dose level 3   11 0 0 0 0 0      
        4 CVP + Inotuzumab dose level 4   5 0 0 0 0 0      
        5 CVP + Inotuzumab dose level 5   11 0 0 0 0 0      
        6 CVP + Inotuzumab MTD   4 4 4 3 1 0      
            41 4 4 3 1 0      
 
  S1318-ALL, Age 65+, Ph±, Blinatumomab 1 T 1 Induction: Ph- 44 31 3 0 0 0 0 06/30/2015 149 58
        2 Induction: Ph+/Ph-like   16 0 0 0 0 0      
            47 3 0 0 0 0      
 
    2 Y 3 Post-remission: Ph- 44 20 2 0 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   12 0 0 0 0 0      
            32 2 0 0 0 0      
 
    3 Y 5 Maintenance: Ph- 44 14 7 1 0 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   10 8 0 0 0 0      
            24 15 1 0 0 0      
 
  S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics 1 Y 0 FLT3 Testing 1670 77 77 75 55 20 5 02/02/2018 199 73
            77 77 75 55 20 5      
 
    2 Y 1 Azacitidine 1670 18 18 17 9 4 0 02/02/2018    
        2 Azacitidine + Nivolumab   17 17 17 13 3 1      
        3 Azacitidine + Midostaurin   17 17 16 14 3 1      
            52 52 50 36 10 2      
 
  S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT 1 N 1 Induction/Consolidation 94 97 0 0 0 0 0 08/25/2010   11
            97 0 0 0 0 0      
 
    2 Y 2 Vincristine/Pred/Dasatinib   22 0 0 0 0 0 08/25/2010    
            22 0 0 0 0 0      
 
    3 Y 3 Allo stem cell transplant 37 43 0 0 0 0 0 08/25/2010    
            43 0 0 0 0 0      
 
    4 Y 4 Dasatinib   42 0 0 0 0 0 08/25/2010    
            42 0 0 0 0 0      
 
Yes E1910-BCR-ABL-neg, B ALL, Blinatumomab 1 E Total Registrations   91 26 14 7 1 0 06/06/2014 1 83
            91 26 14 7 1 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 1 E Total Registrations   75 0 0 0 0 0 08/06/2012   71
            75 0 0 0 0 0      
 
No E1910-BCR-ABL-neg, B ALL, Blinatumomab 0 E Total Registrations   128 39 20 10 3 1 06/06/2014 1 83
            128 39 20 10 3 1      
 
    2 E Total Registrations   57 15 11 4 1 0 06/06/2014    
            57 15 11 4 1 0      
 
    3 E Total Registrations   45 11 7 4 2 0 06/06/2014    
            45 11 7 4 2 0      
 
    4 E Total Registrations   21 7 4 3 1 0 06/06/2014    
            21 7 4 3 1 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 0 E Total Registrations   19 0 0 0 0 0 08/06/2012   71
            19 0 0 0 0 0      
 
    2 E Total Registrations   21 0 0 0 0 0 08/06/2012    
            21 0 0 0 0 0      
 
    3 E Total Registrations   11 0 0 0 0 0 08/06/2012    
            11 0 0 0 0 0      
 
  NHLBIMDS-LEUK, National MDS Study 1 E Total Registrations   16 11 9 5 0 0 12/22/2016 248 104
            16 11 9 5 0 0      
 

20-AUG-2018 6:10

LEUK Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1712 CML, chronic phase, TKI +/- Ruxolitinib 1 Randomization 20-Jul-18